Biology subjects

Westerberg, L.

Publications and source records attributed to Westerberg, L..

5 recordsLinked to original sources

bioRxiv2026

A minimal two-residue C-terminal truncation of AID in adult-onset hyper-IgM syndrome type 2 (HIGM2)

Activation-induced cytidine deaminase (AID), encoded by AICDA, facilitates class-switch recombination (CSR) and somatic hypermutation (SHM) in activated B cells. Loss of AID function causes hyper-IgM syndrome type 2 (HIGM2). While typically autosomal recessive, three C-terminal truncation variants have been reported to act in autosomal dominant manner. We describe a novel heterozygous AICDA nonsense variant, c.589G>T (p.G197*), that truncates the final two C-terminal residues of AID and results in adult-onset HIGM2. Single-cell sequencing of primary patient B cells revealed a complete block in CSR and a [~]10-fold reduction in SHM. AICDA mRNA expression was balanced between wild-type and variant alleles, yet AID protein abundance was reduced to [~]56% with normal subcellular localization. Remarkably, inducible germinal center (iGB) cultures restored CSR in purified naive patient B cells. CRISPR-Cas9 editing of healthy donor B cells confirmed that the iGB platform can rescue B cells harboring heterozygous, but not homozygous, AICDA variants. These results demonstrate that even a two-amino-acid truncation at the AID C-terminus is sufficient to disrupt its function and cause HIGM2.

immunology↗

bioRxiv2026

Parthenolide boosts megakaryocyte maturation and restores platelet responses in Wiskott Aldrich syndrome

Wiskott-Aldrich syndrome (WAS) is an inborn error of immunity with a broad disease spectrum, classified into class I (late onset) or II (early onset) variants. Thrombocytopenia and small platelets are the most consistent findings among patients, difficult to treat and related to development of autoimmunity. To identify new treatment options for thrombocytopenia in WAS, we developed a FACS-based screening for drug repurposing. We identified parthenolide as a lead small molecule that increased WASp abundance in cells with residual WASp expression. Using the megakaryocytic MEG-01 cells, gene edited to express WAS class I and II genetic variants, parthenolide induced megakaryocyte maturation as evident by upregulation of CD61, increased cell size and complexity, increased phosphorylation of ERK1/2, and higher DNA ploidy. We generated a new mouse model harboring a WAS class I missense variant WASp-R88C, corresponding to human WASp-R86C, with reduced expression of WASp. WASp-R88C mice had lower numbers of platelets compared to WT mice. Bone marrow-derived WASp-R88C and WASp-KO megakaryocytes, differentiated in the presence of parthenolide derivative, DMAPT, showed increased ploidy and upregulation of the maturation markers CD61, CD41 and CD42d, resulting in improved platelet production in vitro. Treatment with parthenolide derivative, DMAPT, led to increased platelet numbers in vivo in WASp-R88C mice and dampened the hyperactivation of WAS patient platelets by reducing thrombin-induced CD62P exposure after activation. The identification of parthenolide offers a promising therapeutic approach for WAS patients who are unresponsive or unsuitable for definitive therapies.

cell biology↗

bioRxiv2026

Single cell analysis reveals molecular traits of pediatric lymphoma resistant subclones

The cause of refractory/relapse (R/R) in pediatric lymphoma is unclear. We hypothesized that a stem-like, chemoresistance lymphoma subclone may contribute to R/R. Combining single cell RNA sequencing (scRNA-seq) and immune receptor sequencing (scVDJ-seq) on freshly acquired pediatric non-Hodgkin lymphoma (pNHL n=10), Hodgkin lymphoma (pHL n=5), and 10 reactive lymph nodes from adults or children (a/pReLy), we discovered pediatric-specific progenitor-like lymphocytes, whose cellular program was enriched in pNHL subclones emerging late during clonal evolution, accompanied by loss of immune receptor expression. R-CHOP target gene expression indicated that these subclones may escape first-line treatment, and suggested MSI2, an RNA binding protein, as a potential target. In pHL, the progenitor-like program was found in the tumor microenvironment (TME) but not Hodgkin cells which, during relapse, were myeloid-like and accompanied by CD74highCCL5+ CD8 T cells. In summary, we discovered R/R associated lymphoma subclones in pediatric lymphoma and potential ways to eradicate them. Key messagesO_LIProgenitor-like lymphocytes are uniquely found in pediatric reactive lymph nodes, but not in adults. C_LIO_LIResistant subclones from pNHL acquire progenitor-like program and share MSI2 expression. C_LIO_LIRelapsed Hodgkin cells are monocyte-like and recruit CD74highCCL5+ CD8 T cells. C_LI

cancer biology↗

bioRxiv2025

AID facilitates TET2 demethylation of Irf4 for plasma cell fate in germinal center B cells

Activation-induced cytidine deaminase (AID) is essential for B cell affinity maturation. We investigated why AID deficiency gives rise to giant germinal centers (GC) using the AIDR112H mouse model that is devoid of AID activity. The increased GC response was associated with accumulation of GC B cells in the light zone in immunized AIDR112H mice. AIDR112H GC B cells had reduced capacity to up-regulate IRF4 to initiate plasma cell differentiation, leading to accumulation of a transitional GC population with reduced GL7 expression. Genetic introduction of a high affinity B cell receptor (BCR) was unable to restore plasma cell differentiation of AIDR112H B cells while ectopic expression of catalytic active AID rescued plasma cell generation. AIDR112H impaired recruitment of AID to the Irf4 promoter/enhancer and disrupted the interaction with Ten-eleven Translocation 2 (TET2). Consequently, DNA demethylation at the Irf4 promoter/enhancer was reduced in AIDR112H GC B cells and impeded high Irf4 expression for transition into plasma cells. This data reveals a B cell-intrinsic mechanism that governs the plasma cell fate decision through epigenetic remodeling mediated by AID in cooperation with TET2. Key messagesO_LIAID deficiency leads to accumulation of a transitional (t)GC population of B cells with low expression of GL7 and failure to up-regulate IRF4 C_LIO_LIAID deamination activity is needed to promote up-regulation of IRF4 for plasma cell differentiation. C_LIO_LICo-operation between TET2 and AID facilitates demethylation of the Irf4 enhancer/promoter. C_LI

immunology↗

bioRxiv2022

FOXO dictates initiation of B cell development and myeloid restriction in common lymphoid progenitors

The development of B cells relies on an intricate network of transcription factors critical for developmental progression and lineage commitment. In the B cell developmental trajectory, a temporal switch from predominant Foxo3 to Foxo1 expression occurs at the CLP stage. Utilizing VAV-iCre mediated conditional deletion, we found that the loss of FOXO3 impaired B cell development from LMPP down to B cell precursors, while the loss of FOXO1 impaired B cell commitment and resulted in a complete developmental block at the CD25 negative proB cell stage. Strikingly, the combined loss of FOXO1 and FOXO3 resulted in the failure to restrict the myeloid potential of CLPs and the complete loss of the B cell lineage. This is underpinned by the failure to enforce the early B-lineage gene regulatory circuitry upon a predominantly pre-established open chromatin landscape. Altogether, this demonstrates that FOXO3 and FOXO1 cooperatively govern early lineage restriction and initiation of B-lineage commitment in CLPs. SUMMARYCommon lymphoid progenitors co-express the transcription factors FOXO1 and FOXO3. Removing FOXO1 and FOXO3 at this developmental stage results in regained myeloid potential, failed establishment of the early B cell gene regulatory program, and the complete loss of the B cell lineage.

immunology↗